Valziflocept Reference: HY-P99529 Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE).
Postsynaptic Receptor Antibody Panel (NMDAR2A, NMDAR2B, GluR1) Reference: ARG30131 Postsynaptic Receptor antibody; GluR1 antibody; NMDAR2A antibody; NMDAR2B antibody
Berlimatoxumab Reference: HY-P99472 Berlimatoxumab (ASN-2) is an antibody. Berlimatoxumab can be used for experiment research.
Phospho GluR1 Antibody Panel Reference: ARG30132 Phospho GluR1 antibody; GluR1 antibody; GluR1 Subunit phospho (Ser831) antibody; GluR1 Subunit phospho (Ser845) antibody
Vedolizumab Reference: HY-P9911 Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
Cell Cycle Marker Antibody Panel (Cyclin B1, Cyclin E) Reference: ARG30139 Cell Cycle Marker antibody; Histone H3 phospho (Ser10) antibody; Cyclin E1 antibody; Cyclin B1 antibody
Tilvestamab Reference: HY-P99161 Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas.
Albinterferon alfa-2B Reference: HY-P99427 Albinterferon alfa-2B (alb-IFN) is a recombinant protein consisting of interferon alfa-2b genetically fused to human albumin. Albinterferon alfa-2B can be used for the research of chronic hepatitis C.
Phospho beta Catenin Antibody Panel (Total, pS33, pS37, pT41/pS45) Reference: ARG30144 Phospho beta Catenin antibody; beta Catenin phospho (Thr41 / Ser45) antibody; beta Catenin phospho (Ser33) antibody; beta Catenin phospho (Ser37) antibody; beta Catenin antibody
Stamulumab Reference: HY-P99588 Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research.